The Paraganglioma (Glomus Jugulare Tumor) drugs in development market research report provides comprehensive information on the therapeutics under development for Paraganglioma (Glomus Jugulare Tumor), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Paraganglioma (Glomus Jugulare Tumor). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Paraganglioma (Glomus Jugulare Tumor) and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Paraganglioma (Glomus Jugulare Tumor) by 12 companies/universities/institutes. The top development phase for Paraganglioma (Glomus Jugulare Tumor) is phase ii with 12 drugs in that stage. The Paraganglioma (Glomus Jugulare Tumor) pipeline has 12 drugs in development by companies and one by universities/ institutes. Some of the companies in the Paraganglioma (Glomus Jugulare Tumor) pipeline products market are: Pfizer, Ipsen and Perspective Therapeutics.
The key targets in the Paraganglioma (Glomus Jugulare Tumor) pipeline products market include Vascular Endothelial Growth Factor Receptor 3 (Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 or VEGFR3 or FLT4 or EC 2.7.10.1), Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1), and Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or FLT1 or EC 2.7.10.1).
The key mechanisms of action in the Paraganglioma (Glomus Jugulare Tumor) pipeline product include Cytotoxic To Cells Expressing Somatostatin Receptor Type 2 (SRIF1 or SSTR2) with three drugs in Phase II. The Paraganglioma (Glomus Jugulare Tumor) pipeline products include five routes of administration with the top ROA being Oral and four key molecule types in the Paraganglioma (Glomus Jugulare Tumor) pipeline products market including Small Molecule, and Synthetic Peptide.
Paraganglioma (Glomus Jugulare Tumor) overview
Abnormal growth of chromaffin cells, a type of nerve cell found throughout the body leads to paraganglioma also known as glomus jugulare tumor. It is a rare form of neuroendocrine tumor. These tumors can be found in adrenal glands or outside of it especially in carotid artery. Cause is idiopathic. Headache, high blood pressure, faster pulse rate, sweating is some of the commonly seen symptoms. Paragangliomas can be either malignant or benign in nature and genetic mutations are believed to be one of the causes. Diagnosed by physical examination, urine test, blood catecholamine test, PET scan and other radiographic tests. If malignant only preventive or symptomatic care provided majorly beta-blockers if blood pressure is high. If cancerous chemo followed by radiation surgical procedure to remove the tumor.
For a complete picture of Paraganglioma (Glomus Jugulare Tumor)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
